[{"indications": "Indications\u00a0HIV infection in combination with other antiretroviral drugs", "name": "NEVIRAPINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "5 Infections", "5.3 Antiviral drugs", "5.3.1 HIV infection", "Non-nucleoside reverse transcriptase inhibitors", "NEVIRAPINE"], "cautions": "Cautions\u00a0chronic hepatitis B or C, high CD4 cell count, and\r\nwomen (all at greater risk of hepatic side-effects\u2014if plasma HIV-1\r\nRNA detectable, manufacturer advises avoid in women with CD4 cell\r\ncount greater than 250 cells/mm3 or in men with CD4 cell\r\ncount greater than 400 cells/mm3 unless potential benefit\r\noutweighs risk); interactions: Appendix 1 (nevirapine)Hepatic disease\u00a0Potentially life-threatening\r\nhepatotoxicity including fatal fulminant hepatitis reported usually\r\nin first 6 weeks; close monitoring required\r\nduring first 18 weeks; monitor liver function\r\nbefore treatment then every 2 weeks for 2 months then after 1 month\r\nand then regularly; discontinue permanently\r\nif abnormalities in liver function tests accompanied by hypersensitivity\r\nreaction (rash, fever, arthralgia, myalgia, lymphadenopathy, hepatitis,\r\nrenal impairment, eosinophilia, granulocytopenia); suspend if severe abnormalities in liver function tests but no hypersensitivity\r\nreaction\u2014discontinue permanently if significant\r\nliver function abnormalities recur; monitor\r\npatient closely if mild to moderate abnormalities in liver function\r\ntests with no hypersensitivity reactionRash\u00a0Rash, usually in first 6 weeks,\r\nis most common side-effect; incidence reduced if introduced at low\r\ndose and dose increased after 14 days; monitor closely for skin reactions during first 18 weeks; discontinue permanently if severe rash or if rash\r\naccompanied by blistering, oral lesions, conjunctivitis, facial oedema,\r\ngeneral malaise or hypersensitivity reactions; if rash mild or moderate may continue without interruption but dose\r\nshould not be increased until rash resolvesCounselling\u00a0Patients should be told\r\nhow to recognise hypersensitivity reactions and advised to discontinue\r\ntreatment and seek immediate medical attention if severe skin reaction,\r\nhypersensitivity reactions, or symptoms of hepatitis develop", "side-effects": "Side-effects\u00a0rash including Stevens-Johnson syndrome and rarely,\r\ntoxic epidermal necrolysis (see also Cautions above); nausea, hepatitis\r\n(see also Hepatic Disease above), headache; less commonly vomiting, abdominal pain, fatigue, fever, and myalgia; rarely diarrhoea, angioedema, anaphylaxis, hypersensitivity reactions (may\r\ninvolve hepatic reactions and rash, see Hepatic Disease above), arthralgia,\r\nanaemia, and granulocytopenia (more frequent in children); see also Osteonecrosis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/69475.htm", "doses": [" 200\u00a0mg once daily of \u2018immediate-release\u2019 preparation\r\nfor first 14 days then (if no rash present) 200\u00a0mg twice daily of\r\n\u2018immediate-release\u2019 preparation or 400\u00a0mg once daily of modified-release\r\npreparation; child under 18 years see BNF for children", "Duration of once daily dose regimen of \u2018immediate-release\u2019\r\npreparation should not exceed 28 days; if rash not resolved within\r\n28 days, alternative treatment should be sought. If treatment interrupted\r\nfor more than 7 days, restart using the once daily dose regimen of\r\nthe \u2018immediate-release\u2019 preparation for the first 14 days as for new\r\ntreatment", "If a dose is more than 8 hours late\r\nwith the \u2018immediate-release\u2019 preparation (or more than 12 hours late\r\nwith the modified-release preparation), the missed dose should not\r\nbe taken and the next dose should be taken at the usual time"], "pregnancy": "Pregnancy\u00a0although manufacturer advises caution, may be appropriate\r\nto use if clearly indicated; see also Pregnancy"}]